Cargando…
Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients
Among 242 Japanese pancreatic cancer patients, three patients (1.2%) encountered life-threatening toxicities, including myelosuppression, after gemcitabine-based chemotherapies. Two of them carried homozygous CDA*3 (CDA208G>A [Ala70Thr]), and showed extremely low plasma cytidine deaminase activit...
Autores principales: | Ueno, H, Kaniwa, N, Okusaka, T, Ikeda, M, Morizane, C, Kondo, S, Sugiyama, E, Kim, S R, Hasegawa, R, Saito, Y, Yoshida, T, Saijo, N, Sawada, J |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2661788/ https://www.ncbi.nlm.nih.gov/pubmed/19293806 http://dx.doi.org/10.1038/sj.bjc.6604971 |
Ejemplares similares
-
Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer
por: Okusaka, T, et al.
Publicado: (2004) -
Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?
por: Ueno, H, et al.
Publicado: (2007) -
Circulating endothelial cells and other angiogenesis factors in pancreatic carcinoma patients receiving gemcitabine chemotherapy
por: Kondo, Shunsuke, et al.
Publicado: (2012) -
Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine
por: Ikeda, Masafumi, et al.
Publicado: (2017) -
hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA
por: Aughton, Karen, et al.
Publicado: (2021)